Výsledky vyhledávání

Supplemental Figure 1 from Development of a Novel c-MET–Based CTC Detection Platform

Immunofluorescence characterization of EpCAM and c-MET in cell lines. Immunofluorescence of SNU5, HeLa and SIHA cell lines, with (clockwise from top left of each panel) external c-MET, EpCAM, DAPI from EpCAM slide, and DAPI from c-MET slide.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7049de3339d03a774c7531325244cb04
https://doi.org/10.1158/1541-7786.22515081.v1

Zobrazit plný text záznamu

Supplemental Figure 2 from Development of a Novel c-MET–Based CTC Detection Platform

CD45+/CK+ cells captured with c-MET separated by disease site (2A). Boxplot of all samples from cancer patients versus healthy controls (2B). Representative sample of dual positive cells (2C).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216faed9fadba3b7f33943650873f728
https://doi.org/10.1158/1541-7786.22515078

Zobrazit plný text záznamu

Development of a Novel c-MET–Based CTC Detection Platform

Publikováno v: Molecular Cancer Research. 14:539-547

Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a89adc14084660d474f24c09cb489c
https://doi.org/10.1158/1541-7786.mcr-16-0011

Zobrazit plný text záznamu

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Autor: Andrew J. Armstrong, Julie Kephart, Patrick Healy, Daniel J. George, Colleen Soleau, Kelly Mundy, Evan Y. Yu, Tomasz M. Beer, Carolyn Winters, Rhonda L. Bitting, Joshi J. Alumkal, Rachel Slottke, Carey Hobbs, Susan Halabi

Publikováno v: European journal of cancer (Oxford, England : 1990). 81

Background Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. Methods This was a multisite singl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f7ca99d570d0a5a43f9176af01fbe9
https://pubmed.ncbi.nlm.nih.gov/28629596

Zobrazit plný text záznamu

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

Publikováno v: Prostate cancer and prostatic diseases. 19(1)

In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690787b24e4e1585a68305504b68c073
https://pubmed.ncbi.nlm.nih.gov/26754260

Zobrazit plný text záznamu

Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)

Autor: Carolyn Winters, Kelly Mundy, Evan Y. Yu, Colleen Soleau, Daniel J. George, Carey Hobbs, Susan Halabi, Rachel Slottke, Joshi J. Alumkal, Patrick Healy, Andrew J. Armstrong

Publikováno v: Journal of Clinical Oncology. 33:5025-5025

5025 Background: PI3K pathway activation is common in mCRPC. BKM120 (buparlisib) is an oral, pan-class I PI3 kinase inhibitor. Preclinical data demonstrated a reciprocal feedback loop between PI3K ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e606487fbb0b92ffa74a76213b6a3aa
https://doi.org/10.1200/jco.2015.33.15_suppl.5025

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání